AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion

AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) announced on July 21 that it would invest $50 billion in the United States by 2030, becoming the most recent pharmaceutical company to make this commitment as impending tariffs threaten to drive up costs in the sector.

AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion

Pixabay/Public Domain

The company claims that plans for a new production facility specializing in chronic illnesses are part of the investment. The multibillion-dollar facility would support the company’s oral GLP-1s and the company’s metabolic and weight-management portfolio.

According to the company, the Virginia plant would be AstraZeneca’s biggest manufacturing investment in the world. The investments coincide with President Trump’s threats of levying tariffs of up to 200% on medications manufactured overseas. Before the tariffs take effect, companies would have up to a year and a half to reshore their supply lines.

AstraZeneca PLC (NASDAQ:AZN) is a prominent player in the pharmaceutical sector, especially for its work on rare disease and cancer treatments. The company has a strong reputation in the healthcare industry thanks to its history of medical advancements.

While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.